Michels, Erik H. A.
Butler, Joe M.
Reijnders, Tom D. Y.
Cremer, Olaf L.
Scicluna, Brendon P.
Uhel, Fabrice
Peters-Sengers, Hessel
Schultz, Marcus J.
Knight, Julian C.
van Vught, Lonneke A.
van der Poll, Tom
de Beer, Friso M.
Bos, Lieuwe D. J.
Glas, Gerie J.
Hoogendijk, Arie J.
van Hooijdonk, Roosmarijn T. M.
Horn, Janneke
Huson, Mischa A.
Schouten, Laura R. A.
Straat, Marleen
Wieske, Luuk
Wiewel, Maryse A.
Witteveen, Esther
Bonten, Marc J. M.
Cremer, Olaf M.
Ong, David S. Y.
Frencken, Jos F.
Klouwenberg, Peter M. C. Klein
Koster‐Brouwer, Maria E.
van de Groep, Kirsten
Verboom, Diana M.
,
Funding for this research was provided by:
European Union’s Horizon 2020 (847786 (FAIR), 847422 (ImmunoSep))
Dutch Kidney Foundation (Nr. 19OK009)
Wellcome Trust Investigator Award (204969/Z/16/Z)
Innovation Fund for Medical Sciences (2018-I2M-2-002)
ZonMW (09150161910033)
Article History
Received: 4 October 2022
Accepted: 5 December 2022
First Online: 13 December 2022
Declarations
:
: This study was part of the Molecular Diagnosis and Risk Stratification of Sepsis (MARS) project (ClinicalTrials.gov identifier NCT0195033). The MARS project was a prospective observational study in two tertiary teaching hospitals in the Netherlands. Inclusion of patients was done using an opt-out method approved by the institutional review boards of both hospitals (IRB No. 10-056C).
: There are no competing interests.